IL302640A - Use of isatuximab for the treatment of multiple myeloma - Google Patents

Use of isatuximab for the treatment of multiple myeloma

Info

Publication number
IL302640A
IL302640A IL302640A IL30264023A IL302640A IL 302640 A IL302640 A IL 302640A IL 302640 A IL302640 A IL 302640A IL 30264023 A IL30264023 A IL 30264023A IL 302640 A IL302640 A IL 302640A
Authority
IL
Israel
Prior art keywords
individual
month
antibody
serum
cycles
Prior art date
Application number
IL302640A
Other languages
English (en)
Hebrew (he)
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of IL302640A publication Critical patent/IL302640A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
IL302640A 2020-11-03 2021-11-02 Use of isatuximab for the treatment of multiple myeloma IL302640A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063109305P 2020-11-03 2020-11-03
US202163239108P 2021-08-31 2021-08-31
PCT/US2021/072193 WO2022099257A1 (en) 2020-11-03 2021-11-02 Use of isatuximab for the treatment of multiple myeloma

Publications (1)

Publication Number Publication Date
IL302640A true IL302640A (en) 2023-07-01

Family

ID=78825149

Family Applications (1)

Application Number Title Priority Date Filing Date
IL302640A IL302640A (en) 2020-11-03 2021-11-02 Use of isatuximab for the treatment of multiple myeloma

Country Status (8)

Country Link
US (1) US20220135696A1 (cg-RX-API-DMAC7.html)
EP (1) EP4240416A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023550311A (cg-RX-API-DMAC7.html)
AU (1) AU2021376374A1 (cg-RX-API-DMAC7.html)
CA (1) CA3197381A1 (cg-RX-API-DMAC7.html)
IL (1) IL302640A (cg-RX-API-DMAC7.html)
TW (1) TW202233235A (cg-RX-API-DMAC7.html)
WO (1) WO2022099257A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913777XA (en) 2013-03-13 2020-03-30 Sanofi Sa Compositions comprising anti-cd38 antibodies and carfilzomib

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP3421494A1 (en) * 2017-06-29 2019-01-02 Sanofi Use of isatuximab in combination with an anti-pd-1 antibody
MX2020007429A (es) * 2018-01-12 2020-10-15 Takeda Pharmaceuticals Co Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38).
IL285110B2 (en) * 2019-01-28 2025-11-01 Sanofi Sa Methods of treating multiple myeloma
US20200330594A1 (en) * 2019-04-19 2020-10-22 Janssen Biotech, Inc. Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
CN120501855A (zh) * 2019-05-14 2025-08-19 赛诺菲-安万特美国有限责任公司 给予抗cd38抗体以治疗多发性骨髓瘤的方法

Also Published As

Publication number Publication date
AU2021376374A1 (en) 2023-06-29
CA3197381A1 (en) 2022-05-12
TW202233235A (zh) 2022-09-01
WO2022099257A1 (en) 2022-05-12
EP4240416A1 (en) 2023-09-13
US20220135696A1 (en) 2022-05-05
JP2023550311A (ja) 2023-12-01

Similar Documents

Publication Publication Date Title
Mould et al. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development
Mould et al. Drug development of therapeutic monoclonal antibodies
Dirks et al. Population pharmacokinetics of therapeutic monoclonal antibodies
Li et al. Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
JP7712206B2 (ja) 多発性骨髄腫の処置方法
US20250145701A1 (en) Bispecific antibody and application thereof
IL266112B1 (en) Anti-edb antibodies and antibody-drug conjugates
CN116322769A (zh) 用于治疗多发性骨髓瘤的方法
WO2018067819A1 (en) Compositions and methods for treatment of cancers
WO2024184349A1 (en) Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies
JP2019530704A (ja) がんの処置のためのアベルマブの投与レジメン
US20220135696A1 (en) Use of isatuximab for the treatment of multiple myeloma
JP2025138745A (ja) 再発性および/または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用
TW202545572A (zh) 治療表現ceacam5的癌症之方法
CA3245572A1 (en) USE OF ISATUXIMAB IN COMBINATION WITH OTHER AGENTS FOR THE TREATMENT OF MULTIPLE MYELOMA
CN109641053A (zh) 给药方案
CN116761627A (zh) 艾萨妥昔单抗用于治疗多发性骨髓瘤的用途
RU2858309C2 (ru) Применение изатуксимаба для лечения рецидивирующей и/или рефрактерной множественной миеломы
IL303350A (en) Preparations containing an antibody against HER2/NEU and their use
AU2024318231A1 (en) Treatment of atopic dermatitis
WO2024112561A1 (en) Methods for the treatment of myasthenia gravis
JP2026513770A (ja) 抗ctla4抗体を使用して黒色腫を治療する方法
IL324392A (en) Antibodies targeting human leukocyte antigen cathepsin g peptide complex
BR122024006481A2 (pt) Conjugados de anticorpo-fármaco, composição farmacêutica e seus usos, processo para a produção de um conjugado de anticorpo-fármaco, anticorpo, polinucleotídeo, vetor, célula hospedeira, método para produzir o anticorpo e método para detectar domínio b extra de fibronectina